Matthew herper
Combating cancer with big data
While still in their 20s, Nat Turner and Zach Weinberg built a $2 billion company to pursue an impossible dream—to conquer the Big C. They've not only made fast progress—they've also gotten rich trying
Regeneron's billionaire founder fights for responsible pricing. But look who's talking
Leonard Schleifer condemns greed at other drug firms. But what about the $37,000 price tag on his eczema drug?
Forever Young: Ned David is challenging the ravages of ageing
Now on his fifth startup, Ned David has the blueprint for creating a lucrative biotech. His latest project: A company that will take on the ravages of ageing
Loxo: One patient at a time
Companies large and small are competing to attack rare genetic mutations that cause cancer. The reason? Great science and high drug prices. The result? Soaring stock prices
Incyte: The right chemistry
Incyte has one cancer blockbuster, and it's got Wall Street banking on another. Its secret: Embracing an older age of pharma